Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,292 papers from all fields of science
Search
Sign In
Create Free Account
2-Bromoergocryptine Mesylate
Known as:
Bromocriptine Mesylate
, 2-Bromoergocryptine Mesylate [Chemical/Ingredient]
, Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, monomethanesulfonate (salt), (5'alpha)-
Expand
The mesylate salt of bromocriptine, a semisynthetic ergot alkaloid with dopaminergic, antidyskinetic, and antiprolactinemic activities. Bromocriptine…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
22 relations
Acromegaly
Amenorrhea
Bromocriptine
Bromocriptine 0.8 MG Oral Tablet [Cycloset]
Expand
Narrower (2)
Cycloset
Parlodel
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2011
Review
2011
An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development.
C. Viereck
,
P. Boudes
Contemporary Clinical Trials
2011
Corpus ID: 11252389
2004
2004
First reported pediatric case of systemic lupus erythematosus associated with prolactinoma.
P. Reuman
Arthritis & Rheumatism
2004
Corpus ID: 20799011
There is much interest in the possibility that prolactin influences disease activity in systemic lupus erythematosus (SLE). We…
Expand
2002
2002
Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen.
H. Przuntek
,
S. Bittkau
,
+15 authors
D. Volc
Archives of Neurology
2002
Corpus ID: 17098137
BACKGROUND The complex pharmacological profile of the antiparkinsonian drug budipine influences neurotransmission beyond the…
Expand
1994
1994
Recurrent plurihormonal bimorphous pituitary adenoma producing growth hormone, thyrotropin, and prolactin.
I. Félix
,
S. Asa
,
K. Kovacs
,
É. Horváth
,
H. Smyth
Archives of Pathology & Laboratory Medicine
1994
Corpus ID: 24591478
A 48-year-old man with visual disturbances and subtle features of acromegaly had elevated serum thyrotropin (thyroid-stimulating…
Expand
1989
1989
Bromocriptine and pleuropulmonary disease.
S. Melmed
,
G. Braunstein
Archives of Internal Medicine
1989
Corpus ID: 7964486
Bromocriptine mesylate, a long-acting dopamine agonist, is a semisynthetic ergot-derived alkaloid that has been used clinically…
Expand
1987
1987
Prolactin modulates the gonadotropin response to the negative feedback effect of testosterone in immature male rats.
V. Chandrashekar
,
A. Bartke
,
Kara J. Sellers
Endocrinology
1987
Corpus ID: 23144634
The effects of hyperprolactinemia (hyperPRL) and hypoprolactinemia (hypoPRL) on pituitary gonadotropin secretion and the feedback…
Expand
1986
1986
In vivo evidence for dopaminergic regulation of the canine pituitary intermediate lobe.
R. Kemppainen
,
J. Sartin
Acta Endocrinologica
1986
Corpus ID: 35627275
In order to examine regulation of pituitary intermediate lobe secretion, plasma immunoreactive (i)ACTH, cortisol, and alpha-MSH…
Expand
1981
1981
Regression of pituitary prolactinoma with bromocriptine administration.
C. Velentzas
,
D. Carras
,
J. Vassilouthis
Journal of the American Medical Association (JAMA…
1981
Corpus ID: 29600934
IT HAS been demonstrated that treatment with bromocriptine mesylate can reduce the size of pituitary prolactinomas. 1,2 The…
Expand
1980
1980
Bromocriptine Mesylate (Parlodel) in the Management of Amenorrhea/Galactorrhea Associated with Hyperprolactinemia
F. Cuellar
Obstetrics and Gynecology
1980
Corpus ID: 31568994
The efficacy and safety of bromocriptine mesylate (5 to 7.5 mg per day for up to 24 weeks) were studied in 22 clinical trials…
Expand
1980
1980
Bromocriptine for an acromegalic patient. Improvement in cardiac function and carpal tunnel syndrome.
R. Luboshitzky
,
D. Barzilai
Journal of the American Medical Association (JAMA…
1980
Corpus ID: 37446564
A 64-year-old woman with active acromegaly of 33 years' duration, severe carpal tunnel syndrome, and subclinical heart disease…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE